# compensation mesothelioma

Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma - PubMed » Caring for patients with MPM is challenging and complex. Health care professionals believe under-utilisation of chemotherapy is occurring, primarily due to clinician nihilism and lack of medical oncology referral. Pubmed.ncbi.nlm.nih.gov

Depression and Complicated Grief, and Associated Factors, of Bereaved Family Members of Patients Who Died of Malignant Pleural Mesothelioma in Japan » Objectives: we investigated the prevalence and associated factors of depression and complicated grief (CG) among bereaved family members of malignant pleural mesothelioma (MPM) patients in Japan. Methods: Bereaved family members of MPM patients (n = 72)… Ncbi.nlm.nih.gov

Applying Definitions of “Asbestos” to Environmental and “Low-Dose” Exposure Levels and Health Effects, Particularly Malignant Mesothelioma » Although asbestos research has been ongoing for decades, this increased knowledge has not led to consensus in many areas of the field. Two such areas of controversy include the specific definitions of asbestos, and limitations in understanding exposure-response… Ncbi.nlm.nih.gov

Mesothelioma Compensation Claims Solicitors - No Win No Fee » Speak with our mesothelioma claims experts - No Win No Fee - "Market-leading industrial disease practice with an outstanding reputation" - Call 0800 358 3848 Fieldfisher.com

Management of Advanced Pleural Mesothelioma—At the Crossroads » The management of pleural mesothelioma has changed with the demonstration that first-line checkpoint blockade therapy improves survival. This review covers issues of relevance to the practicing medical oncologist, with an emphasis on the palliative setting and on new information. Until recently, standard systemic therapy for mesothelioma was combination chemotherapy with platinum and pemetrexed. In 2020, combination immunotherapy with ipilimumab and nivolumab was approved as first-line systemic therapy for mesothelioma following release of the results from the CheckMate 743 trial. This trial showed improved overall survival for patients receiving ipilimumab and nivolumab over those treated with platinum and pemetrexed chemotherapy. When the survival results were examined by histologic subtype, the survival benefit was most significant in those with nonepithelioid mesothelioma, a group for which combination immunotherapy is now standard of care. The most important outstanding issue from CheckMate-743 is a bett Ascopubs.org

Understanding Mesothelioma Prognosis & Tips to Help Improve It » A mesothelioma prognosis is a patient's overall outlook. Here's everything you need to know including prognosis by mesothelioma type & improving prognosis. Asbestos.com

The Significance of Short Latency in Mesothelioma for Attribution of Causation: Report of a Case with Predisposing Germline Mutations and Review of the Literature » Malignant mesothelioma is a tumour of the serosal membranes, related to asbestos exposure. Median latency is in the order of 40 years in various registries, but small numbers of cases with shorter latencies have long been reported and often dismissed… Ncbi.nlm.nih.gov

Explaining the Invisibility of Asbestos-Related Diseases in the Taiwan Workers’ Compensation System - Yawen Cheng, Yi-Ling Huang, Lukas Jyuhn-Hsiarn Lee, 2022 » Occupational asbestos exposure was prevalent in Taiwan, but asbestos-related diseases (ARDs) have rarely been recognized. We conducted in-depth face-to-face int… Journals.sagepub.com